The pragmatic use of apomorphine at the end of life.
Parkinson's Disease (PD) is an irreversible degenerative neurological disorder with no known cure. Apomorphine is a potent short-acting D1/D2 dopamine agonist administered sub-cutaneously that is used in the treatment of PD. Optimising PD medication is an important aspect of end of life care. There are no previously reported cases of apomorphine providing symptom relief in terminal care of PD patients. This case highlights its potential benefits for symptom control at the end of life.
Dewhurst
F
F
Northumbria Healthcare NHS Trust, Newcastle upon Tyne, UK. drfelicitywerrett@doctors.org.uk
Lee
M
M
Wood
B
B
D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001058:Apomorphine / Q000009:adverse effects / Q000627:therapeutic use*; D001767:Blinking; D003680:Deglutition Disorders / Q000503:physiopathology; D004294:Domperidone / Q000008:administration & dosage; D006801:Humans; D018476:Hypokinesia / Q000503:physiopathology; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D013727:Terminal Care / Q000379:methods*
D000932:Antiemetics; D000978:Antiparkinson Agents; D004294:Domperidone; D001058:Apomorphine